207 related articles for article (PubMed ID: 22541681)
1. Stabilization of hepatitis C associated collapsing focal segmental glomerulosclerosis with interferon alpha-2a and ribavirin.
Sperati CJ
Clin Nephrol; 2013 Sep; 80(3):231-4. PubMed ID: 22541681
[TBL] [Abstract][Full Text] [Related]
2. Long-term response to peginterferon in hepatitis C virus-associated nephrotic syndrome from focal segmental glomerulosclerosis.
Shah HH; Patel C
Ren Fail; 2013 Sep; 35(8):1182-5. PubMed ID: 23879705
[TBL] [Abstract][Full Text] [Related]
3. Rapidly deteriorating renal function with membranoproliferative glomerulonephritis Type 1 associated with hepatitis C treated successfully with steroids and antiviral therapy: a case report and review of literature.
Ahmed MS; Wong CF; Shawki H; Kapoor N; Pandya BK
Clin Nephrol; 2008 Apr; 69(4):298-301. PubMed ID: 18397706
[TBL] [Abstract][Full Text] [Related]
4. Peginterferon alfa-2a plus ribavirin for the treatment of dual chronic infection with hepatitis B and C viruses.
Liu CJ; Chuang WL; Lee CM; Yu ML; Lu SN; Wu SS; Liao LY; Chen CL; Kuo HT; Chao YC; Tung SY; Yang SS; Kao JH; Liu CH; Su WW; Lin CL; Jeng YM; Chen PJ; Chen DS
Gastroenterology; 2009 Feb; 136(2):496-504.e3. PubMed ID: 19084016
[TBL] [Abstract][Full Text] [Related]
5. Sustained hepatitis C virus clearance and increased hepatitis B surface antigen seroclearance in patients with dual chronic hepatitis C and B during posttreatment follow-up.
Yu ML; Lee CM; Chen CL; Chuang WL; Lu SN; Liu CH; Wu SS; Liao LY; Kuo HT; Chao YC; Tung SY; Yang SS; Kao JH; Su WW; Lin CL; Yang HC; Chen PJ; Chen DS; Liu CJ;
Hepatology; 2013 Jun; 57(6):2135-42. PubMed ID: 23322699
[TBL] [Abstract][Full Text] [Related]
6. Occurrence of hepatocellular carcinoma 13 years after successful antiviral treatment for HCV infection.
Puoti C; Lanzetta G; Scotti E
J Gastrointestin Liver Dis; 2016 Sep; 25(3):408-9. PubMed ID: 27689211
[No Abstract] [Full Text] [Related]
7. Baseline anti-NS4a antibodies in combination with on-treatment quantitative HCV-RNA reliably identifies nonresponders to pegylated interferon-ribavirin combination therapy after 4 weeks of treatment.
Orlent H; Desombere I; Hansen B; Van Vlierberghe H; Haagmans B; De Knegt RJ; Schalm SW; Leroux-Roels G; Janssen HL;
Eur J Gastroenterol Hepatol; 2010 Dec; 22(12):1443-8. PubMed ID: 21389795
[TBL] [Abstract][Full Text] [Related]
8. [Treatment with pegylated interferon and ribavirin in patients co-infected by human immunodeficiency virus and hepatitis C virus].
Marcos Sánchez F; Albo Castaño MI; Casallo Blanco S
Rev Clin Esp; 2007 Mar; 207(3):150-1; author reply 151-2. PubMed ID: 17397643
[No Abstract] [Full Text] [Related]
9. Scleromyxedema secondary to hepatitis C virus and successfully treated with antiviral therapy.
Smith JA; Kalimullah FA; Erickson CP; Peng LS
Dermatol Online J; 2015 Sep; 21(9):. PubMed ID: 26437283
[TBL] [Abstract][Full Text] [Related]
10. [HIV/HCV double infection: combination is a clear therapy option].
Reich B
Dtsch Med Wochenschr; 2004 Jul; 129(28-29):1590. PubMed ID: 15274242
[No Abstract] [Full Text] [Related]
11. Interferon/pegylated interferon and ribavirin in HCV-associated kidney disease with or without cryoglobulinemia.
Bruchfeld A; Lindahl K; Stahle L; Schvarcz R
J Hepatol; 2006 Feb; 44(2):432-3; author reply 433. PubMed ID: 16338023
[No Abstract] [Full Text] [Related]
12. Catatonia associated with pegylated interferon-α 2b and ribavirin for hepatitis C.
Quinn D; Kuchler E; Deming P; Arora S
Psychosomatics; 2012; 53(4):400-1. PubMed ID: 22748752
[No Abstract] [Full Text] [Related]
13. Interferon-gamma with peginterferon alpha-2a and ribavirin in nonresponder patients with chronic hepatitis C (ANRS HC16 GAMMATRI).
Couzigou P; Pérusat S; Bourlière M; Trimoulet P; Poynard T; Leroy V; Marcellin P; Foucher J; Bronowicki JP; Chêne G;
J Gastroenterol Hepatol; 2013 Feb; 28(2):329-34. PubMed ID: 23190183
[TBL] [Abstract][Full Text] [Related]
14. The effect and safety of the treatment of recurrent hepatitis C infection after orthotopic liver transplantation with pegylated interferon α2b and ribavirin.
Perrakis A; Yedibela S; Schuhmann S; Croner R; Schellerer V; Demir R; Hohenberger W; Müller V
Transplant Proc; 2011 Dec; 43(10):3824-8. PubMed ID: 22172854
[TBL] [Abstract][Full Text] [Related]
15. Early discontinuation of ribavirin in HCV-2 and HCV-3 patients responding to Peg-interferon alpha-2a and ribavirin.
Andriulli A; Cursaro C; Cozzolongo R; Iacobellis A; Valvano MR; Mangia A; Minerva N; Bacca D; Stanzione M; Scuteri A; Montalto G; Andreone P
J Viral Hepat; 2009 Jan; 16(1):28-35. PubMed ID: 18761603
[TBL] [Abstract][Full Text] [Related]
16. A change of peginterferon may permit continuation of antiviral therapy in hepatitis C virus-infected patients with interstitial pneumonitis.
Shimada M; Yoshida S; Kornek M; Kim SJ; Schuppan D
Liver Int; 2010 Nov; 30(10):1552-4. PubMed ID: 20557455
[No Abstract] [Full Text] [Related]
17. [Effectiveness of peg-interferon and ribavirin for hepatitis C in a patient with hypertension and diminished kidney function].
Bátyi E; Szegedi J
Orv Hetil; 2008 May; 149(19):889-92. PubMed ID: 18450549
[TBL] [Abstract][Full Text] [Related]
18. Pegylated interferon-alpha2a and ribavirin in HIV-hepatitis C coinfected patients.
Expert Rev Anti Infect Ther; 2004 Jun; 2(3):341-2. PubMed ID: 15490503
[No Abstract] [Full Text] [Related]
19. [Peginterferon-alfa-2b or -alfa-2a and ribavirin combined treatment in hepatitis C infection].
Szalay F
Orv Hetil; 2010 Feb; 151(7):271-3. PubMed ID: 20133247
[No Abstract] [Full Text] [Related]
20. Hepatitis C virus-related heat-insoluble cryoglobulinemia and thrombotic microangiopathy.
Wu H; Zou HB; Xu Y; Zhang L; Du YJ; Yu JY; Lu RH; Li X
Am J Med Sci; 2013 Oct; 346(4):345-8. PubMed ID: 23744520
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
